PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Billing Codes · Medical Policy · MS · Hematology, Oncology, Transplant SurgeryMedium impact

Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Allogeneic hematopoietic cell transplantation using a myeloablative conditioning regimen may be considered medically necessary as a treatment of chronic myeloid leukemia. Allogeneic hematopoietic cell transplantation using a reduced-intensity conditioning regimen may be considered medically necessary for individuals who meet clinical criteria for an allogeneic HCT but are not considered candidates for a myeloablative conditioning allogeneic HCT, and autologous HCT is investigational for chronic myeloid leukemia. The policy was reviewed 07/27/2026 with policy statements unchanged, and ICD-9 procedure and diagnosis codes were removed from the code reference.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01Obtain prior authorization through Case Management from Blue Cross & Blue Shield of Mississippi before a covered transplant procedure, because no benefits will be provided for a covered transplant procedure unless the member receives prior authorization.
02For State and School Employee subscribers, all bone marrow or stem cell transplants must be certified as medically necessary by the Plan's Utilization Review Vendor, and no benefits will be provided for any transplant procedure unless prior approval for the transplant is obtained.
03For reduced-intensity allogeneic HCT, document that the individual meets clinical criteria for an allogeneic HCT and is not a candidate for a myeloablative conditioning regimen, such as an individual whose age (typically older than 60 years) or comorbidities (for example liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, or low Karnofsky Performance Status score) preclude a standard myeloablative regimen.
04Do not bill autologous HCT for chronic myeloid leukemia as medically necessary, because the policy classifies it as investigational.
05Services not documented to be medically necessary will not be paid.

Codes mentioned

3820538206382403824138242S2150C92.10C92.11C92.12

Original notice

Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account